BioSpace News Archive

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.

Horizon Therapeutics plc Announces Data from the TEPEZZA ® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting.

Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients.

Erasca, Inc. (Nasdaq: ERAS) today announced promising preliminary Phase 1b data for ERK inhibitor ERAS-007 in patients with metastatic BRAF V600E-mutated (BRAFm) colorectal cancer (CRC) and provided a portfolio update.

PolyPid Ltd. announced it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s minimum bid price rule and approval from Nasdaq to transfer the listing of the ordinary shares of the Company from The Nasdaq Global Market to The Nasdaq Capital Market.

Humacyte, Inc. announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Jefferies Healthcare Conference, in New York, NY on June 9, 2023.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that Jean-François Formela, M.D. is retiring from its board of directors, effective June 15, 2023.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) announced the final overall survival (OS) results of the JUPITER-02 study presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting.

Procaps Group, S.A., a leading integrated international healthcare and pharmaceutical services company, announced its 1Q23 financial results.